Skip to content

Treatment of the Hypertensive Leg Ulcers by PRF Application

Treatment of the Hypertensive Leg Ulcers by PRF Application

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01957124
Enrollment
10
Registered
2013-10-08
Start date
2013-10-31
Completion date
2017-07-31
Last updated
2017-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive Leg Ulcer

Brief summary

Hypertensive leg ulcers are very painful and difficult to treat ulcers. Their treatment is not well established. We want to study the efficacy of PRF applications on the pains related to those ulcers. PRF (Platelet-Rich Fibrin) is an autologous fibrin clot, obtained extemporaneously from patient's blood, without any additive nor complex manipulation. It contains blood platelets and white blood cells, trapped in fibrin during clot formation. PRF (Platelet-Rich Fibrin) is form immediately after blood punction in a dry tube, that does not contain any anticoagulant. Coagulation naturally occurs within few minutes, and tubes are placed in a centrifuge: red blood cells are separated from the fibrin clot thanks to difference of density, and blood platelets and white blood cells are trapped in the fibrin clot. The fibrin clot is then rapidly applicated on the ulcer surface for four days. Our hypothesis is that platelet growth factors and cytokines, liberated during platelet activation, could help to treat hypertensive leg ulcers, that are caused by a vascular spasm.

Detailed description

2 to 8 PRF (depending on the ulcer surface), applied on painful hypertensive leg ulcer, and covered by a dressing for 4 days. Afterwards, dressings are made in a classical way. If needed (persistence of important pain), the PRF application can be repeated after 7 days.

Interventions

PROCEDUREPRF (Platelet-Rich Fibrin)

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* hypertensive leg ulcer * important pain (\>= 5/10)

Exclusion criteria

* significant venous deficiency * significant arterial deficiency * other leg ulcers * any active diseases such as infection, neoplasia, auto-immune disease

Design outcomes

Primary

MeasureTime frameDescription
Pain auto evaluation (spontaneous and caused by local care)Pain was assessed by self-assessment Single Digital Scale - Pain felt in the past 24 hours;\- Pain experienced during the last ulcer care. Ulcers are described using the: * Size * Presence or absence of necrosis on the bottom and banks * Presence or absence of purplish banks

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026